Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. HUBS
4. NUE
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress

Inovio Pharmaceuticals Reports 2016 Second Quarter Financial Results

August 8, 2016 8:00 AM EDT

PLYMOUTH MEETING, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to $5.3 million. Total operating expenses were $24.4 million compared to $20.4 million. The net loss attributable to common stockholders was $18.7 million, or $0.26 per share, compared to $6.2 million, or $0.09 per share.

Revenue

The increase in revenue was primarily due to an increase in development payments from our DARPA Ebola... More

Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs

August 4, 2016 8:02 AM EDT

PLYMOUTH MEETING, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovios regulatory strategies, including leadership over regulatory submissions, regulatory compliance, advertising and promotion review, and registrations to support Inovios product pipeline.   

Dr. J. Joseph Kim, Inovios President & CEO, said, Ami has shown technical excellence and leadership in successfully moving our DNA-based... More